OriGene Logo

Customer Login

Checkout as a new customer

Creating an account has many benefits:

  • See order and shipping status
  • Track order history
  • Check out faster
Create an Account

ErbB 3 (ERBB3) Human shRNA Plasmid Kit (Locus ID 2065)

Be the first to review this product
SKU
TR320343
ERBB3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
  $883.00
In Stock*

Frequently Bought Together (2)

TA803694 ERBB3 mouse monoclonal antibody, clone OTI3E10 (formerly 3E10) 100 ul
$447.00
TF81001 TurboFectin Transfection Reagent (1 mL in 1 vial)
1 ml in 1 vial
$530.00

Other products for "ErbB 3 or NM_001005915"

Specifications
Specifications
Product Data
Locus ID 2065
Synonyms c-erbB-3; c-erbB3; ErbB-3; erbB3-S; FERLK; HER3; LCCS2; MDA-BF-1; p45-sErbB3; p85-sErbB3; p180-ErbB3
Vector pRS
E. coli Selection Ampicillin
Mammalian Cell Selection Puromycin
Format Retroviral plasmids
Components ERBB3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 2065). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq NM_001005915, NM_001982, NM_001982.1, NM_001982.2, NM_001982.3, NM_001005915.1, BC082992, BC082992.1, BC002706, BC041579, BM837872, NM_001982.4
UniProt ID P21860
Summary This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized. provided by RefSeq, Jul 2008
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Storage Store at -20°C
Shipping Ambient
Reviews
Write Review
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations
Blair, Wu, Zahari et al
Proteomics (2014)
Cited by 14
AI Summary: OriGene’s shRNA construct (TR320343) targeting ERBB3 mRNA was used to generate stable cell lines with HER3 knockdown, enabling the study of HER3’s role in MAP kinase pathway activation by different PIK3CA mutations.
Snippet: (ab8245;Abcam). RNA interference Short-hairpin RNA constructs were purchased from Origene (TR320343) to target ERBB3 mRNA, and were used to create stable shRNA expressing cell lines as previously described [14]. ... Cite SaveSaving
microRNA-205 regulates HER3 in human breast cancer
Iorio, Casalini, Piovan et al
Cancer Res (2009) 69 (6), 2195-200 DOI: 10.1158/0008-5472.CAN-08-2920
AI Summary: In this study, OriGene's HER3 expression plasmid (RC211307) and HER3-specific siRNA (SR321082) were used to modulate HER3 levels in breast cancer cells, enabling the authors to demonstrate that miR-205 directly targets and downregulates HER3, thereby inhibiting downstream Akt signaling and enhancing sensitivity to anticancer therapies.
Showing 1-2 of 2 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products